# Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa

> **NCT02320812** · PHASE1,PHASE2 · COMPLETED · sponsor: **jCyte, Inc** · enrollment: 28 (actual)

## Conditions studied

- Retinitis Pigmentosa (RP)

## Interventions

- **BIOLOGICAL:** human retinal progenitor cells

## Key facts

- **NCT ID:** NCT02320812
- **Lead sponsor:** jCyte, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-07-19
- **Final completion:** 2017-07-19
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02320812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02320812, "Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02320812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*